Peritonitis from *Leclercia adecarboxylata*: An emerging pathogen

Sreedhar Adapa | Venu Madhav Konala | Faiza Nawaz | Tariq Javed | Hemant Dhinra | Irene A. Gutierrez | Magda L. Ramirez

**INTRODUCTION**

*Leclercia adecarboxylata* (*L adecarboxylata*) is a gram-negative bacillus which can rarely cause infections in humans, particularly in immunocompromised individuals. Peritonitis is a very serious complication that is often responsible for catheter loss and switching the dialysis modality in patients undergoing peritoneal dialysis. There has been increased recognition of peritonitis caused by rare organisms. We report a case of 48-year-old female patient, who presented with abdominal pain and cloudy effluent. Peritoneal fluid effluent showed elevated white blood cell (WBC) with cell count of 2200 cells/μL (with 96% neutrophils). Peritoneal fluid culture grew *L adecarboxylata*. Patient was treated with intraperitoneal cefazolin for 3 weeks. Posttreatment peritoneal dialysis effluent was clear with WBC count of 2 cells/μL and repeat fluid culture was negative. *L adecarboxylata* is a motile gram-negative bacillus isolated from drinking water, belonging to Enterobacteriaceae family first described in 1962, by Leclerc as *Escherichia adecarboxylata*. In 1986, it was renamed *L adecarboxylata* in honor of Leclerc, as it was distinct genus phenotypically and genetically. *L adecarboxylata* causing infections in humans are very rare, mostly limited to immunosuppressed or with serious chronic medical conditions. This bacterium is susceptible to most of the antibiotics, but cases with antibiotic resistance have been reported. There have been very few cases of *L adecarboxylata* peritonitis reported in the literature.

**CASE REPORT**

A 48-year-old female with history of end-stage renal disease secondary to diabetic nephropathy presented with nausea,
vomiting, fever, and abdominal pain for two-day duration. Patient has been on automated peritoneal dialysis for 2 years and never had an episode of peritonitis. Patient lives in a ranch home and takes care of cattle. Other medical problems include the following: hypertension, diabetes, anemia of chronic disease, and coronary artery disease. Patient had low-grade fever and her other vital signs were stable. Physical examination revealed diffuse abdominal tenderness and no drainage from exit site. No tenderness was elicited along the tunnel of peritoneal dialysis catheter. Peritoneal dialysis effluent showed elevated WBC with cell count of 2200 cells/μL (with 96% neutrophils). Gram stain revealed >100 WBC, and no organisms seen. Patient received empirical treatment with intraperitoneal Vancomycin and Ceftazidime. Effluent grew gram-negative bacilli, which was identified as *Leclercia adecarboxylata* by VITEK mass spectrometry using Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology. The organism was reported to be pan sensitive to antibiotics. Intraperitoneal antibiotic therapy was narrowed to Cefazolin, which was continued for 3 weeks. Posttreatment peritoneal dialysis effluent was clear, with WBC count of 2 cells/μL and repeat fluid culture was negative.

### 3 | DISCUSSION

*Leclercia adecarboxylata* is an ubiquitous motile facultative anaerobic gram-negative bacillus of Enterobacteriaceae family. The organism has been isolated from multiple environmental sources including water, animals, and humans. In our patient, possible source of infection can be from water source or farm animals (cattle, hen’s eggs, normal gut flora in pigs), which has been reported in literature before.

*Leclercia adecarboxylata* is an opportunistic organism, which can affect patients who are immunocompromised or with chronic medical conditions and have been isolated from various body fluids like blood, stool, sputum, urine, peritoneal fluid and pus. It can present as an isolated organism or as a part of poly microbial infection. Rarely, it has been reported to cause infections in immunocompetent patients. *L. adecarboxylata* was isolated from blood cultures of an asymptomatic platelet donor.

*Leclercia adecarboxylata* causing peritonitis has been described in the literature, where the patient was treated with intraperitoneal antibiotics, without removal of peritoneal dialysis catheter. It has been reported in patients undergoing hemodialysis with tunneled catheter, which highlights the prevalence of bacteria in patients with end stage renal disease. It is also known to infect temporary catheters in immunocompromised patients. *L. adecarboxylata* is described to cause bacteremia, endocarditis, cholecystitis, and wound infections related to trauma and burns as well as cellulitis.

*Leclercia adecarboxylata* can be misinterpreted as *E coli*, due to similar properties biochemically. It is very important to accurately identify *L. adecarboxylata* in the clinical specimen to guide diagnosis, treatment, and epidemiological information. The epidemiological prevalence of *L. adecarboxylata* is under reported until recently, given bacterial assays were not sensitive in differentiating it from *E coli*. Automated identification systems and mass spectrometry in clinical microbiological laboratories play a very critical role in isolating atypical organisms like *L. adecarboxylata*, promptly and precisely. Chromogenic CPSE (translucent agar) media is utilized to differentiate *E coli* from *L. adecarboxylata* in small laboratories, where automated expensive laboratory techniques are not available. Gene sequencing techniques like 16S RNA (Ribonucleic acid) has been used sparsely to confirm the organism. MALDI-TOF mass spectrometry helps to identify species better than conventional biochemical systems (92.2% vs 83.1%) and also resulted in better genus identification. MALDI-TOF mass spectrometry identified 97.7% of Enterobacteriaceae species, precisely.

*Leclercia adecarboxylata* is susceptible to most of the common antibiotics; however, strains producing extended-spectrum beta-lactamases have been reported.

As per De Mauri et al, strategies to treat catheter-related bacteremia are as follows.

| Temporary catheters which can be easily substituted | Short-course antibiotic monotherapy (1-2 wk) and replace the catheter |
|----------------------------------------------------|----------------------------------------------------------------------|
| Temporary catheters in complicated patients with a high risk of an adverse result following catheter replacement | Long-term therapy with two antibiotics and maintain the catheter in situ with constant monitoring |
| Permanent tunneled hemodialysis catheters | Long course (2-4 wk) with at least two intravenous antibiotics, combined with “locked-in” therapy; retaining the catheter with constant monitoring |

### 4 | CONCLUSION

*Leclercia adecarboxylata* is a rare cosmopolitan organism, but capable of causing serious and life-threatening infections. Microbiological techniques have been successful in identifying this organism more frequently. Prompt diagnosis and timely intervention will prevent further complications as in our patient.

### ETHICAL APPROVAL

This is a case report, so exemption has been provided.
CONFLICT OF INTEREST

The authors declare no conflict of interests.

Informed Consent: Both informed consent and written consent were obtained from the patient.

AUTHOR CONTRIBUTION

SA, VMK, HD: prepared, reviewed and submitted the Manuscript, TJ, FN, IG, MR: involved in management and preparing case report.

ORCID

Sreedhar Adapa https://orcid.org/0000-0001-5608-5654
Venu Madhav Konala https://orcid.org/0000-0003-1953-8815

REFERENCES

1. Leclerc H. Etude biochimique d’enterobacteriaceae pigmentees. 
   Ann Inst Pasteur. 1962;102:726-741.
2. Tamura K, Sakazaki R, Kosako Y, Yoshizaki E. Leclercia adequarboxylata Gen. Nov., Comb. Nov., formerly known as Escherichia adequarboxylata. 
   Curr Microbiol. 1986;13:179-184.
3. Yu C, Hongwei G, Yanming Z, et al. Analysis of the bacterial diversity existing on animal hide and wool: development of a preliminary PCR-restriction fragment length polymorphism fingerprint database for identifying isolates. 
   JAOAC Int. 2012;95:1750-1754.
4. Stepien-Pysniak D. Occurrence of gram-negative bacteria in hens’ eggs depending on their source and storage conditions. 
   Pol J Vet Sci. 2010;13:507-513.
5. Schierack P, Walk N, Reiter K, Weyrauch KD, Wieler LH. Composition of intestinal Enterobacteriaceae populations of healthy domestic pigs. 
   Microbiology. 2007;153:3830-3837.
6. Hess B, Burchett A, Huntington MK. Leclercia adequarboxylata in an immunocompetent patient. 
   J Med Microbiol. 2008;57:896-898.
7. Stock I, Burak S, Wiedemann B. Natural antimicrobial susceptibility patterns and biochemical profiles of Leclercia adequarboxylata strains. 
   Clin Microbiol Infect. 2004;10:724-733.
8. Davenport P, Land KJ. Isolation of Leclercia adequarboxylata from the blood culture of an asymptomatic platelet donor. 
   Transfusion. 2007;47:1816-1819.
9. Chao CT, Hung PH, Huang JW, Tsai HB. Cycler cassette rupture with Leclercia adequarboxylata peritoneal dialysis peritonitis. 
   Perit Dial Int. 2014;34:131-132.
10. Fattal O, Deville JG. Leclercia adequarboxylata peritonitis in a child receiving chronic peritoneal dialysis. 
    Pediatr Nephrol. 2000;15:186-187.
11. De Mauri A, Chiarinotti D, Andreoni S, Molinari GL, Conti N, De Leo M. Leclercia adequarboxylata and catheter-related bacteremia: review of the literature and outcome with regard to catheters and patients. 
    J Med Microbiol. 2013;62:1620-1623.
12. Anuradha M. Leclercia adequarboxylata isolation: case reports and review. 
    J Clin Diagn Res. 2014;8:DD03-DD04.
13. Çiçek M, Tuncer Ö, Biçakçigil A, Gürsoy NC, Otu B, Sancak B. A rarely isolated Gram-negative bacterium in microbiology laboratories: Leclercia adequarboxylata. 
    Acta Microbiol Immunol Hung. 2018;65:241-244.
14. Patel R. New developments in clinical bacteriology laboratories. 
    Mayo Clin Proc. 2016;91:1448-1459.
15. van Veen SQ, Claas EC, Kuiper EJ. High-throughput identification of bacteria and yeast by matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical microbiology laboratories. 
    J Clin Microbiol. 2010;48:900-907.
16. Mazzariol A, Zuliani J, Fontana R, Cornaglia G. Isolation from blood culture of a Leclercia adequarboxylata strain producing an SHV-12 extended-spectrum b-lactamase. 
    J Clin Microbiol. 2003;41:1738-1739.

How to cite this article: Adapa S, Konala VM, Nawaz F, et al. Peritonitis from Leclercia adequarboxylata: An emerging pathogen. 
Clin Case Rep. 2019;7:829–831. 
https://doi.org/10.1002/ccr3.2094